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Abstract
Background: Chondrosarcoma is the second most frequent malignant bone tumor. Grade I chondrosarcoma (syn.:
atypical cartilaginous tumor) is classified as an intermediately and locally aggressive neoplasm and typically is treated
less aggressively (i.e., by intralesional curettage). Does the data regarding local recurrence (LR) and metastatic disease
justify this?
Methods: From 1982 to 2014, 37 consecutive patients with G1 chondrosarcoma had been resected or curetted. The
margin was defined as R0 (wide resection) or R1 (marginal resection). All patients were followed for evidence of local
recurrence or metastatic disease. Overall and recurrence-free survival were calculated, and various potentially prognostic
factors were evaluated.
Results: In 23 patients (62%), the tumor was widely (R0) resected, whereas in 14 patients, (38%) the resection was
marginal (R1). Overall survival was 97% after 5 years, 92% after 10 years, and 67% after 20 years. Five-year local recurrence-
free survival was 96%. Ten-year local recurrence-free survival was 83%. Local recurrence-free survival showed a significant
correlation to margin status but no correlation to location or age. None of the patients with local recurrence died during
the follow-up. One patient had metastatic disease at initial presentation, and a further five patients developed metastatic
disease during follow-up. Metastatic disease proofed to be a highly significant factor for survival but was not correlated to
local recurrence.
Conclusions: There was no significant correlation between the outcome and the primary tumor location. Marginal
resection was a risk factor for LR, but there was no significant difference in the overall survival in patients with or
without LR. Metastatic disease (16%) was more common than expected from the literature and a significant predictor
for poor overall survival.
Keywords: Chondrosarcoma, Low-grade, Surgery, Curettage, Margin status, Recurrence, Prognostic factors
Background
Representing more than 20% of all malignant tumors of
the bone, chondrosarcoma (CS) is the third most common
primary malignant bone tumor following osteosarcoma
and multiple myeloma [1]. Chondrosarcomas are most
often seen in adult age and are a very heterogenous group
with a diverse behavior depending on the histological
subtype. The most common subtype is conventional CS.
Clear cell CS appears to have the best prognosis while
dedifferentiated CS has the worst outcome [2]. For
conventional CS, tumor grading and anatomic location
are the main predictors of outcome [2–4].
Therapy consists mainly of surgical resection. In critical
locations, radiotherapy in high dosage (if applicable) is
effective as an adjuvant or as the sole therapy [5] while
chemotherapy appears to be less effective [6, 7]. The
definition of adequate surgical margins varies within the
literature [4]. In high-grade chondrosarcomas, a wide
resection is the standard to prevent local recurrence. In
low-grade chondrosarcoma, intralesional curettage is
commonly used although controversial [8–10]. In a large
literature review in 2017, Chen et al. found only 1.2%
metastatic disease and no difference in local recurrence
with respect to surgical margins [11].
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The WHO classification of grade I chondrosarcoma
(atypical cartilaginous tumor) as an intermediately and
locally aggressive neoplasm implies that there is no or
only rarely metastatic disease with low-grade chondro-
sarcoma [12]. This definition comprises the benign clin-
ical behavior of the lesions, but it is known that even
grade I CS carries a risk of metastasis in up to 6% of
cases [12].
With intralesional curettage becoming more and more
common in low-grade chondrosarcoma, it appears
important to take a closer look at the influence of less
aggressive (intralesional) surgical margins and outcomes
in grade I CS. Does a wider margin prevent metastases
or local recurrence in low-grade CS? Is the location of
the lesion a predictor of outcome in low-grade lesions as
it is in high-grade CS [13, 14]?
The main aim of this retrospective study hence was to
have a closer look at this very selective and homogenous
group of patients with primary low-grade conventional
CS treated at a single tumor center to determine
prognostic factors for overall and recurrence-free sur-
vival. The secondary aim was a comparison of our data
to the literature for quality-of-care reasons.
Materials and methods
Patients
From 1982 through 2014, 87 consecutive patients with
central chondrosarcoma of the extremities, the pelvis, and
the trunk wall were treated at our institution. All patients
had a diagnosis of chondrosarcoma based on histological,
radiological, and clinical features.
Preoperatively, mainly magnetic resonance imaging
(MRI) and in some cases computed tomography (CT)
were used to define size and location of the tumor. A CT
scan of the chest was obtained to rule out or prove meta-
static disease.
Margins and inclusion criteria
All patients underwent surgical resections. The margin
was defined as R0 if a rim of healthy tissue around the
lesion was present (wide resection) or R1 if the margins
were contaminated as in close resections or curettages.
From those 87 patients, 37 showed a low-grade (G1)
histology and were classified as atypical cartilaginous
tumors. Inclusion criteria for this study were therefore a
histology-proven G1 grading in the resected specimen
with or without proven metastatic disease.
Statistical analysis
All patients were followed for evidence of local recur-
rence or distant metastasis in general by MRI scans and
chest x-rays. Due to the long investigation period with
considerable changes in the ability to detect small metas-
tases, especially in the lungs, and small local recurrences,
the number of metastatic cases as also local recurrences
might be underestimated. Subsequently, recurrence-free
survival would be overestimated. Therefore, in addition,
overall survival is calculated from the time of surgery to
last follow-up or death in deceased patients. Overall and
recurrence-free survival were calculated by the Kaplan-
Meier method. Significance analysis was performed
using the log-rank test or the chi-square test. The data
analysis software used was SPSS 24®.
Results
The mean age of the 12 female and 25 male patients was
47.1 years (range 17–84 years). The upper extremity was
involved in 4 cases (humerus 2, radius 1, hand 1), and the
lower extremity in 23 cases (femur 15, tibia 4, fibula 2, feet
2). Five patients had the lesion in the trunk (scapula 4, ribs
1), and five in the pelvis (4 os ilium, 1 os pubis). Sixteen
(43%) showed extraosseous tumor growth.
The median duration of symptoms was 19.8 months
(range 0–153 months). Nineteen patients (51%) com-
plained of pain, 3 (8%) complained about swelling, and 5
(11%) suffered from a pathological fracture, and in 6
cases (16%), the lesion was found as an incidental find-
ing. Occasionally, there were neurological symptoms or
a loss of the range of motion. Thirty-one patients (84%)
had a biopsy taken before surgery. In four cases, the
biopsies showed benign cartilaginous lesions, later classi-
fied as false negatives. Six patients had undergone intra-
lesional surgery elsewhere with either intramedullary
nails or endoprostheses prior to presenting to our insti-
tution, and the tumor had been overlooked or underesti-
mated in these cases. One patient had metastatic disease
at the time of diagnosis.
In 28 patients, the tumor was resected or curetted and
the defect, as necessary, was filled with allogenic bone
graft. A reconstruction with megaendoprostheses was
performed in 8 (22%), and an amputation in 1 case (2%).
In 23 patients (64%), the tumor was widely (R0) resected,
whereas in 14 patients (38%), the resection was marginal
(R1). There were no R2 resections. Histology showed a
conventional low-grade chondrosarcoma in all patients.
In pelvic lesions, 66% were marginal resections com-
pared to 92% at the lower extremities and 33% at the
upper extremities. There were no marginal resections at
the trunk.
In five patients (14%), revisions due to complications
had to be performed. The complications included loos-
ening of an endoprosthesis in two, neurological impair-
ment because of a malpositioned osteosynthesis screw,
additional and more aggressive tumor resection, and
deep wound infection in one case each.
The mean follow-up in our series was 127.9 months
(range 0–344 months). Only 3 patients had a follow-up
time of less than 24 months, and 13 patients (35%) had a
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follow-up of less than 5 years. Five patients died during
the follow-up: one within the first year, one after 7 years,
and three after more than 15 years (Fig. 1).
Overall survival was 97% after 5 years, 92% after 10 years,
and 67% after 20 years (Fig. 1). Five-year local recurrence-
free survival was 96%. Ten-year local recurrence-free
survival was 83%. In total, 5 (14%) patients developed local
recurrences: only 1 of them during the first 5 years and 4
after 10 years. In our patients, local recurrence-free survival
showed a significant correlation with the margin status
(Fig. 2; p = 0.035) but no correlation with the location or
the patients’ age. This was confirmed by means of multi-
variate analysis (Table 1).
None of the patients with local recurrence (LR) died
during the follow-up, and only one showed LR and
metastatic disease (MD).
Six patients (16%) in our study developed metastases,
whereas one patient had an initial spinal metastasis but
remained free of disease after resection of that lesion. In
five patients (14%), metastatic disease developed during
follow-up (four pulmonary, one bone). Mean metastasis-
free survival was 86% after 5 years and 75% after 20
years. Four of our patients deceased during the follow-
up period (Fig. 3). In the multivariate analysis, there was
no correlation between the surgical margins and the
location in respect to metastatic disease.
Metastasis proved to be a significant predictive factor
for survival (Fig. 3; p < 0.0001). Age over 50 showed a
trend in respect to worse overall survival, but this failed
significance testing (Fig. 4; p = 0.078). Only one of the
patients (5%) without soft tissue extension died during
the follow-up period compared to four patients (27%)
with extraosseous infiltration (n.s.) (Fig. 5; p = 0.07).
Local recurrence and lesion location showed no signifi-
cance in predicting overall survival.
Discussion
Grade I chondrosarcoma is generally assumed to be an
entity of low malignancy with 5-year survival rates of
90% and more and with little to no metastatic disease
[12, 15]. There is, however, no consensus on prognostic
factors (i.e., location of the lesion) or the influence of
surgical margins (wide resection vs. curettage) and the
clinical outcomes in grade I CS.
Although tumor location and patient age have been
identified as being strong predictive factors for overall
survival in patients with conventional chondrosarcoma
in previous publications [16, 17], in our series of patients
with low-grade CS, we observed no statistically signifi-
cant correlation between overall survival and patient age
at diagnosis (p = 0.078) or tumor location (p = 0.238).
A 14% LR rate in our group of patients is similar to
previously published numbers of LR in low-grade CS,
ranging between 0 and 26% [18–21]. Marginal resection
was a significant predictor for LR (p = 0.037) in our
series. It is known that local recurrence in high-grade
chondrosarcoma is associated with poorer outcome, but
there is still some debate about whether this is true for
low-grade chondrosarcoma as well [22–25]. We were
not able to demonstrate a significant correlation between
local recurrence and overall survival in this group of pa-
tients (p = 0.6). Several authors have described a
Fig. 1 Survival of all patients with conventional G1 chondrosarcoma
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progression of the tumor and the occurrence of distant
metastases in association with local recurrence [12, 22,
26, 27]. However, there also are studies that were unable
to find such a correlation between LR and MD [23, 24].
In our patients, there was also no correlation between
LR and MD with only one patient having both LR and
MD. This discrepancy to some of the published litera-
ture might be due to the limited mean follow-up of the
patients with LR in our group of only 77 months, espe-
cially since Schwab et al. described that poor outcomes
in patients with LR become significant only beyond 10
years [22].
As mentioned above, there is no consensus on
whether or not LR has any significance when it comes to
overall survival in low-grade CS. However, many studies
have shown that inadequate surgical margins lead to a
higher rate of LR, necessitating further surgery with add-
itional risks [10, 23, 24, 27]. Some studies suggest to
combine intralesional curettage with adjuvant measures
such as the application of poly-methyl-methacrylat
(PMMA) or cryosurgery to reduce LR rates [20, 28, 29].
The metastatic potential of low-grade CS is controver-
sially discussed in the literature with rates ranging
between 0 and 6% [18, 24, 28, 30]. In our study, one
patient already had MD at initial assessment and five pa-
tients developed MD during follow-up (16%). A possible
reason for this observation could be the longer follow-up
of our study with a mean metastasis-free survival of 76
months. Studies which did not describe any MD often re-
port a much shorter follow-up period [31, 32]. However,
there are also published studies with a long follow-up and
little or no MD as well [9, 20]. This might reflect the
difficulty in differentiating between atypical chondrogenic
tumors and benign chondromas.
In this study, MD proved to be a significant predictor
for a poor outcome (p < 0.0001) which is consistent with
the findings of other authors. However, we found no
significant correlation between the surgical procedure and
Fig. 2 Influence of surgical margins on local recurrence-free survival (p = 0.035)
Table 1 Local recurrence in relation to surgical margins and tumor location
Local recurrence No Yes p value 5-year LRFS (%) 10-year LRFS (%) 15-year LRFS (%) p value
R0 22 (96%) 1 (4%) 0.037 100 92 92 0.035
R1 10 (71%) 4 (29%) 90 79 54
Upper extremity 4 (100%) 0 (0%) 0.097 100 100 100 0.238
Lower extremity 18 (78%) 5 (22%) 94 71 60
Pelvis 5 (100%) 0 (0%) 100 100 100
Trunk 5 (100%) 0 (0%) 100 100 100
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MD. Interestingly, 2 out of 8 patients with intralesional
curettage and 4 out of 16 patients with extraosseous
tumor growth developed MD but there was no statistically
significant correlation between surgical margins and MD
(p = 0.45) or extraosseous growth and MD (p = 0.21).
Although not statistically significant, the high rate of
MD and the higher mortality suggests that extraosseous
tumor growth may be a different subtype of CS after all,
since it appears to behave differently than regular low-
grade CS.
Conclusion
While the location of the primary tumor is a strong
prognostic factor for high-grade CS (i.e., pelvic lesions
have a worse prognosis), in this study, there was no
significant difference between patients’ outcomes and
Fig. 3 Metastatic disease has a significant negative influence on overall survival (p < 0.0001)
Fig. 4 Overall survival of patients in relation to patient age (≤ 50 vs. > 50 years) (n.s.)
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the tumor location. Marginal resection (R1) was a risk
factor for LR, but compared to high-grade CS, there was
no significant difference in the overall survival of
patients with or without LR. Patients with soft tissue
extension of the tumor showed a worse prognosis, but
this failed significance testing. MD was more common
(16%) than expected and a significant predictor for poor
overall survival.
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